Entrada Therapeutics, Inc.

US$4.89As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:TRDAHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (27.12%)
Div yield —
ROE (59.88%)
Biotechnology
Beta (5Y) (0.15)
PE TTM —
TSR TTM (29.64%)
Mkt cap US$178.5M
ROIC (303.41%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$5.47
11.84%
(75.04%)
Hold 12|9|5|11|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.12
0.11
0.11
0.10
20.55%
6.35%
(2.97%)
(12.28%)
Revenue$M
8.863
8.801
8.548
8.472
(2.91%)
(4.91%)
(5.78%)
(5.38%)
Peers (US$178.5M)
Cap (US$)
PE
176.9M
—
Capital
TTM
5Y
10Y
Leveragex
0.853
(0.035)
(0.036)
EBIT/Intx
0.193
0.115
0.121
Own earn%
(133.61)
2.37
2.85
Sh yield%
46.04
46.53
38.87
Owners
Insiders/Inst%
11.26
59.50
Short interest%
5.23
SBC / revenue%
4.76
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
9–18
$1 testx
0.0
Incr. ROIC%
16